In recent studies, BCL2 inhibitors have been suggested as a possible therapeutic approach to breast cancer, both due to their apoptosis-enabling effect and their potential synergistic effect with tamoxifen as an ER inhibitor. The gene discussed is ESR1; the disease is breast cancer.